Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* BALTHROP PATRICK J	2. Issuer Name and Ticker or Trading Symbol Oxford Immunotec Global PLC [ OXFD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 3/8/2021
(Street) ABINGDON, OXFORDSHIRE, X0 OX14 4RZ (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	3/8/2021		D		8081	D	$22 ⁽¹⁾	0	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$11.62	3/8/2021		D			3728	⁽²⁾	1/29/2026	Ordinary Shares	3728	$10.38 ⁽³⁾	0	D
Stock Option (Right to Buy)	$11.62	3/8/2021		D			14914	⁽²⁾	1/29/2026	Ordinary Shares	14914	$10.38 ⁽³⁾	0	D
Stock Option (Right to Buy)	$8.65	3/8/2021		D			7457	⁽²⁾	6/28/2026	Ordinary Shares	7457	$13.35 ⁽³⁾	0	D
Stock Option (Right to Buy)	$14.46	3/8/2021		D			7457	⁽²⁾	6/6/2027	Ordinary Shares	7457	$7.54 ⁽³⁾	0	D
Stock Option (Right to Buy)	$14.49	3/8/2021		D			7457	⁽²⁾	6/19/2028	Ordinary Shares	7457	$7.51 ⁽³⁾	0	D
Stock Option (Right to Buy)	$14.44	3/8/2021		D			7457	⁽²⁾	6/18/2029	Ordinary Shares	7457	$7.56 ⁽³⁾	0	D
Stock Option (Right to Buy)	$12.96	3/8/2021		D			9494	⁽²⁾	6/24/2030	Ordinary Shares	9494	$9.04 ⁽³⁾	0	D

Explanation of Responses:
(1)	Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
(2)	In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
(3)	Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BALTHROP PATRICK J C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE, X0 OX14 4RZ	X